为何靶向前列腺特异性膜抗原是前列腺癌管理中的颠覆性变革
前列腺特异性膜抗原(PSMA)在前列腺腺癌高表达、在良性和前列腺外组织表达有限,是理想靶点。近5年靶向PSMA的诊断与治疗药物快速发展,PSMA PET显像在高危局限期、生化复发和晚期患者中似乎优于传统影像;以177Lu为代表的β射线放射性药物治疗显示影像学反应显著并可减轻疼痛,安全性一般限于轻度一过性骨髓抑制和因小分子药物唾液腺摄取导致的口干,但总生存获益尚未证实。
要点
- PSMA在前列腺腺癌高表达、在良性和前列腺外组织表达有限,是理想诊治靶点。
- 在高危局限期、治疗后生化复发和晚期患者中,PSMA PET显像似乎优于传统影像。
- 治疗研究多用靶向PSMA的放射性金属如177Lu,安全性一般限于轻度一过性骨髓毒性和口干。
核心结论
- PSMA是前列腺癌诊治的理想靶点,靶向PSMA的药物研究已显示令人鼓舞的结果,但总生存获益尚未证实。
研究设计与样本
- 本文为综述,梳理30余年来靶向PSMA的临床技术发展及近5年诊断与治疗药物的研发进展。
主要发现
- 已开发针对SPECT和PET平台的PSMA显像剂。
- PSMA PET显像在高危局限期、治疗后生化复发和晚期患者中似乎优于传统影像。
- 已发表的治疗研究多使用靶向PSMA的放射性金属递送β射线至转移灶,177Lu是研究最广泛的治疗性放射性核素。
- 抗体和小分子药物的研究均已发表并显示令人鼓舞的结果。
- 安全性一般限于轻度一过性骨髓毒性和因小分子药物唾液腺摄取导致的口干;影像学反应可很显著,并观察到疼痛减轻。
局限性
- 对总生存的影响尚未证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is highly expressed on prostate adenocarcinomas, exhibits only limited expression in benign and extraprostatic tissues, and thus represents an ideal target for the diagnosis and management of prostate cancer. Since its discovery over 30 y ago, significant effort has been made to develop clinical technology targeting PSMA. The last 5 y have seen an explosion of development of new agents targeting PSMA for diagnostic and therapeutic use. Imaging agents targeting PSMA have been developed for SPECT and PET platforms. PSMA PET imaging appears to outperform traditional imaging in the high-risk localized-disease state, in patients with biochemical recurrence after treatment, and in advanced disease. To date, most of the reported clinical studies of therapeutic agents have used PSMA-targeted radiometals to deliver β-radiation to metastatic disease sites, with 177Lu being the most widely investigated therapeutic radioisotope. Studies of both antibodies and small-molecule agents have been published and have demonstrated encouraging results. Safety appears generally limited to mild transient bone marrow toxicity and xerostomia because of uptake of the small-molecule agents in the salivary glands. Radiologic responses can be dramatic, and decreases in pain have been observed. The effect on overall survival, however, has yet to be demonstrated.
引用
- Donin NM, Reiter RE. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med. 2017. PMID: 28986509. doi:10.2967/jnumed.117.191874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。